Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 649: Nivolumab plus ipilimumab or nivolumab plus chemotherapy vs chemotherapy in gastric or gastroesophageal junction cancer
jRCT2080223355Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised trial of nivolumab in gastric cancer (GC) and esophagogastric junction cancer (3 arms), sponsored by Ono Pharmaceutical. Started Oct 2016; status: completed.
02
Drugs
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on jRCT2080223355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223355.